Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-09
DOI
10.1038/s41467-021-21177-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
- (2020) Nina Shah et al. LEUKEMIA
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
- (2020) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma
- (2020) Sarah Gooding et al. BLOOD
- Genome instability in multiple myeloma
- (2020) Carl Jannes Neuse et al. LEUKEMIA
- Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies
- (2020) Jordan Gauthier et al. BLOOD
- Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
- (2020) Nirav N. Shah et al. NATURE MEDICINE
- Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage
- (2019) Dvir Aran et al. NATURE IMMUNOLOGY
- Deciphering the chronology of copy number alterations in Multiple Myeloma
- (2019) Anil Aktas Samur et al. Blood Cancer Journal
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive Integration of Single-Cell Data
- (2019) Tim Stuart et al. CELL
- Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
- (2019) Mattia D’Agostino et al. LEUKEMIA
- Genomic landscape and chronological reconstruction of driver events in multiple myeloma
- (2019) Francesco Maura et al. Nature Communications
- Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
- (2019) Jiali Cheng et al. Frontiers in Oncology
- CONICS integrates scRNA-seq with DNA sequencing to map gene expression to tumor sub-clones
- (2018) Sören Müller et al. BIOINFORMATICS
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
- (2018) Brian A. Walker et al. BLOOD
- Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)
- (2018) Alice Cleynen et al. BLOOD
- Genomics of Multiple Myeloma
- (2017) Sebastien Robiou du Pont et al. JOURNAL OF CLINICAL ONCOLOGY
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- (2017) L. Rasche et al. Nature Communications
- FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
- (2016) Ronglai Shen et al. NUCLEIC ACIDS RESEARCH
- Molecular signatures database (MSigDB) 3.0
- (2011) A. Liberzon et al. BIOINFORMATICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More